Navigation Links
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Date:8/29/2009

PARIS, and PRINCETON, N.J., Aug. 30 /PRNewswire/ -- Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis (EURONEXT: SAN, and NYSE: SNY) and Bristol-Myers Squibb (NYSE: BMY), co-commercialization and co-development partners for PLAVIX((R)) (clopidogrel bisulfate), were sponsors of the study.

CURRENT-OASIS 7 is the largest clinical trial (25,087 patients) to evaluate different dosing regimens of PLAVIX((R)) plus aspirin in a broad range of acute coronary syndrome (ACS) patients (UA/NSTEMI/STEMI). The study was designed to assess the efficacy and safety of an intensified clopidogrel regimen (600 mg loading dose day 1 / 150 mg days 2-7 / 75 mg days 8-30) versus the approved PLAVIX dosage (300 mg loading dose day 1 / 75 mg days 2-30) for patients managed with an early invasive strategy with an intent for percutaneous coronary intervention (PCI).

The primary end-point (cardiovascular death, heart attack, or stroke at thirty days) for the entire study population (including subpopulations of patients that underwent PCI (70%) or not (30%) examining the difference between the high-dose and standard-dose PLAVIX((R)) (clopidogrel bisulfate) regimens did not reach statistical significance (4.2% vs. 4.4%, HR 0.95, p=0.37).

For clinically relevant subgroups that were pre-specified for preliminary analyses, such as the PCI subgroup (70% of the trial population, 17,232 patients), potentially medically relevant differences in patient outcomes were observed. In this subgroup, analysis showed an improvement in outcome fo
'/>"/>

SOURCE sanofi-aventis; Bristol-Myers Squibb
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
4. Directors Forum: PEPFAR and the Global AIDS Response
5. Alfacell Corporation to Present at UBS Global Life Sciences Conference
6. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
7. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
8. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
9. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
10. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  XBiotech announced ... study being conducted in the US for its ... Human™ monoclonal antibody therapy, is being evaluated in ... complicated with cachexia. The primary endpoint of the ... treated patients to a control population provided only ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... CANTEL MEDICAL CORP. (NYSE: CMN ) ... per diluted share, on a 24% increase in sales to a ... compares with net income of $4,274,000, or $0.25 per diluted share, ... 2010.  For the nine months ended April 30, 2011, the Company ...
... Pa., June 8, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical ... treat cancer, today announced the appointment of Mr. Jonathan ... and vice president of corporate development. ... of corporate development and finance experience.  He has led ...
Cached Medicine Technology:Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 2Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 3Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 5TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development 2
(Date:9/2/2014)... New York, New York (PRWEB) September 02, 2014 ... metal-on-metal version of the DePuy Pinnacle hip implant ... jury selection begins today in the U.S. District ... reports. According to court documents, Johnson & Johnson ... 6,000 lawsuits that allege the all-metal hip caused ...
(Date:9/2/2014)... Raton, FL (PRWEB) September 02, 2014 ... audience targeting and multi-channel email marketing is pleased to ... the market, Firearms & Freedom as well ... online properties represent more than one million concerned Americans ... display advertising. , “We are honored to continue ...
(Date:9/2/2014)... research shows a novel polypill increases patient adherence ... heart attack, according to new study results reported ... 2014 in Barcelona, Spain. According to Principal Investigator ... Heart at Icahn School of Medicine at Mount ... de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, ...
(Date:9/2/2014)... San Diego School of Medicine have identified an enzyme ... findings, reported in the current issue of PNAS, offer ... worldwide. An estimated 40,000 women in America will die ... Cancer Society. , "The take-home message of the study ... breast cancer metastasis through a pathway regulated by an ...
(Date:9/2/2014)... associated with many health risks, including heart disease and ... possible way to mitigate one often-overlooked risk: not buckling ... by Sheldon H. Jacobson, a professor of computer science ... are associated with a decrease in seatbelt usage. However, ... in effect. , "Primary seatbelt laws lead to increased ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Enzyme controlling metastasis of breast cancer identified 2Health News:Seatbelt laws encourage obese drivers to buckle up 2
... common problem among women. However statistics show that among people ... with knee joint pain, obese people are in the majority. ... definite about the reasons for the knee pain. //Majority of ... briefly. ,The basic sturcture of knee joint is composed ...
... young as even 3 days old can tell whether someone ... author, doubts that humans have evolved to be sensitive to ... Farroni is a researcher with the Centre for Brain and ... University of London.// ,Farroni, felt that newborns are not ...
... The first major trans-Atlantic telesurgical operation has been carried ... from a patient in eastern France by remotely operating ... for a surgeon to perform an operation on a ... Institute of Telesurgery in Strasbourg say the procedure was ...
... their new study suggested that, along with calcium, protein ... Getting enough calcium is essential for building and maintaining ... men and women who were taking calcium citrate malate ... density increased most in people whose diets contained the ...
... a biomedical engineer at the University of Pittsburgh makes ... your eyes. The prototype device merges the visual outer ... scan of what lies beneath. It creates the effect ... 3D location with the patient, showing blood vessels, muscle ...
... with Alzheimer’s may worsen the symptoms of Parkinson’s ... could improve treatments for these conditions, say US ... up to one-third of Alzheimer’s patients develop Parkinson’s ... ,To research a possible link between ...
Cached Medicine News:Health News:New combined therapy for Knee Joint pain 2Health News:Newborns Know how to make eye contact 2Health News:Calcium and Protein Equals Strong Bones 2Health News:New form of ultrasonic vision 2
Livewire TC steerable ablation catheters are designed for the RF ablation of arrhythmias. They are available in a variety of curves and configurations, including bi-directional catheters for added fl...
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Integrity ADx ... the world's smallest dual-chamber ... advanced pacemaker technology, including ... algorithm, the first U.S. ...
... Frontier II device is designed ... moderate to severe heart failure ... in patients who are symptomatic ... and who have prolonged QRS ...
Medicine Products: